Pharmasyntez Group is one of the leading Russian biopharmaceutical companies operating across various healthcare sectors, including research, production, manufacturing, and distribution of socially significant pharmaceuticals, innovative therapies, and active pharmaceutical ingredients. Pharmasyntez Group operates eight high-tech manufacturing facilities across Russia: in Ussuriysk, Irkutsk, Bratsk, Tyumen, St. Petersburg, Moscow, Kaluga. The annual production volume surpasses 100 million packages. As of 2025, the consolidated revenue of the Pharmasyntez Group reached 50,5 billion rubles. The staff exceeds 6,000 employees. Pharmasyntez develops and manufactures modern pharmaceuticals for a wide range of medical fields, including oncology, hematology, endocrinology, immunology, and cardiology. The company develops and produces pharmaceuticals for orphan diseases, hormonal disorders, infections, autoimmune conditions, cardiovascular diseases, and psychoneurological disorders. The company’s portfolio covers therapies for diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, chronic kidney insufficiency, and parenteral nutrition to support patients in critical conditions. Pharmasyntez encompasses one of Russia’s largest R&D centers for biotechnological drugs. The company’s ongoing research and development endeavors are paving the way for the next generation of innovative therapies for the fields of oncohematology, gynecology, and antiviral treatment. The product portfolio includes over 320 pharmaceutical products. Over 77% of the products manufactured are included in the List of Vital and Essential Drugs (VEDs). Pharmasyntez is the largest investor in the Russian pharmaceutical industry. To date, the company has invested more than 25 billion rubles in the expansion of production facilities and the development of new products.